Viewing nowPregabalin Oral Disintegrating Tablets 50 mg (Pregabalin)
Pregabalin 50mg
Orally disintegrating Tablet · Prescription medication
Hanol Bio Pharma Co., Ltd.

MFDS item code 202600532 · Approved 2026.02.24
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial seizures
This medication is used for the treatment of peripheral and central neuropathic pain in adults. It is also used as an adjunctive treatment for partial seizures in patients with epilepsy and is effective whether or not there are secondary general symptoms. Additionally, it helps in the treatment of fibromyalgia. In summary, it is used to improve symptoms of neuropathic pain, partial seizures in epilepsy, and fibromyalgia.
This medicine is administered orally as pregabalin, with the total daily dose divided into 2 doses, regardless of food. Place it on the tongue and, once it has disintegrated, swallow it without water. This medicine is primarily excreted by the kidneys; therefore, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of the individual patient, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, the dose may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of the individual patient, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of treatment’) 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of the individual patient, the dose may be increased to 300 mg/day after 1 week. If necessary, the dose may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg-450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, the dose may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies have also been conducted at a dose of 600 mg/day; however, there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this medicine is primarily excreted by the kidneys as unchanged drug. Since the clearance of this medicine is directly affected by creatinine clearance, dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the following formula. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered immediately after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosage based on renal function Creatinine clearance (CLcr), (mL/min) ≥60: Initial dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥30-<60: Initial dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥15-<30: Initial dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID Creatinine clearance (CLcr), (mL/min) <15: Initial dose 25 (mg/day), maximum dose 75 (mg/day), QD Supplemental dose after hemodialysis: 25-100, single dose b TID = total daily dose administered in 3 divided doses BID = total daily dose administered in 2 divided doses QD = administered once daily a: The total daily dose (mg/day) should be administered in divided doses as specified in the dosing regimen. b: The supplemental dose refers to a dose administered once as an additional dose. 6. Patients with hepatic impairment Dose adjustment is not required in patients with hepatic impairment. 8. Elderly patients (aged 65 years or older) Dose reduction may be necessary in elderly patients with impaired renal function.
Children under 12 years of age: Administration is not recommended. Adolescent patients aged 12-17 years: Administration is not recommended.
This medication may increase the risk of suicidal thoughts or behavior, so if symptoms of depression or mood changes occur during treatment, it must be reported to a healthcare professional immediately. It should not be used if there is an allergy to this medication's components. Diabetic patients may need to adjust their blood sugar control medications due to weight gain after taking this medication. If allergic reactions such as angioedema occur, discontinue use immediately and consult a healthcare professional. Elderly patients need to be cautious of falls or injuries due to dizziness or drowsiness and should refrain from activities if these symptoms occur. This medication may cause blurred vision, so any changes in vision should be reported to a healthcare professional. Halting this medication suddenly can cause withdrawal symptoms such as insomnia, headache, and anxiety, so it should be gradually reduced after consulting a healthcare professional. Patients with a history of drug abuse should be especially cautious of misuse or dependence on this medication. Patients with decreased kidney function may require dose adjustments of this medication. Patients with severe heart disease should use this medication cautiously and consult a healthcare professional immediately if symptoms of heart failure occur. Taking this medication with other central nervous system depressants or opioid analgesics can increase the risk of respiratory depression, so caution is needed. During early pregnancy, there is a risk of fetal malformations, so women who are pregnant or planning to become pregnant should consult a healthcare professional before taking this medication and use effective contraception. Breastfeeding women should discuss with a healthcare professional regarding the potential transfer of this medication into breast milk and its effects on the infant. It is advisable to avoid dangerous activities such as driving or operating machinery until dizziness or drowsiness symptoms subside. Severe skin reactions may occur, so if symptoms such as rash, redness, or blisters arise, discontinue use immediately and inform a healthcare professional. In cases of overdose, symptoms such as drowsiness, confusion, depression, and seizures may occur, so immediate medical attention should be sought for appropriate treatment. This medication must be stored out of reach of children and should not be transferred to other containers for safety.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent exposure to air or moisture. It is recommended to maintain a storage temperature between 1 to 30 degrees Celsius.
Yellow round oral disintegrating tablet
30 tablets/PTP [10 tablets/PTP x 3], 100 tablets/PTP [10 tablets/PTP x 10]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowPregabalin 50mg
Orally disintegrating Tablet · Prescription medication
Hanol Bio Pharma Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 300mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Hanmi Pharm. Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Hanmi Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.